Nothing Special   »   [go: up one dir, main page]

Peters et al., 2016 - Google Patents

MicroRNA-139 targets phosphodiesterases 3 and 4, and modulates calcium cycling in cardiomyocytes

Peters et al., 2016

View PDF
Document ID
517180919828233359
Author
Peters T
Schönleitner P
Ghigo A
Verhesen W
Rech M
Summer G
Derks W
van Leeuwen R
Zacchigna S
Giacca M
Luiken J
de Windt L
Hirsch E
Antoons G
Heymans S
Schroen B
Publication year
Publication venue
Non-coding RNA species in heart failure

External Links

Snippet

Background Adrenergic signaling in the heart is mediated by the second messenger cyclic AMP (cAMP) and limited by the cAMP-degrading phosphodiesterases (PDEs). cAMP- dependent protein kinase (PKA) is an important effector of adrenergic signaling by …
Continue reading at cris.maastrichtuniversity.nl (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Similar Documents

Publication Publication Date Title
Tijsen et al. The microRNA-15 family inhibits the TGFβ-pathway in the heart
DK2217704T3 (en) Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis
JP5871791B2 (en) Means and methods for neutralizing, preventing and / or determining heart failure or risk of heart failure
Liu et al. Overexpression of miR-142-3p improves mitochondrial function in cardiac hypertrophy
US8691783B2 (en) MicroRNA-24
Shi et al. MiR‐26a‐5p alleviates cardiac hypertrophy and dysfunction via targeting ADAM17
US9611480B2 (en) Means and methods for counteracting, delaying and/or preventing adverse energy metabolism switches in heart disease
AU2009270005B2 (en) Means and methods for counteracting, delaying and/or preventing heart disease
KR102142791B1 (en) Use of miR-204 inhibitors for treating osteoarthritis
Peters et al. MicroRNA-139 targets phosphodiesterases 3 and 4, and modulates calcium cycling in cardiomyocytes
US20130011845A1 (en) Microrna regulating the insulin signaling pathway, and method for screening material for controlling the action of a target thereof
EP4144349A1 (en) Rna interference-inducing nucleic acid comprising 8-oxoguanine, modified nucleic acid binding to microrna comprising 8-oxoguanine, and uses thereof
US20210310008A1 (en) Parn as a biomarker and therapeutic target
Di Mauro Novel insights into the protective role of miR-133a in the heart and its therapeutic application for the treatment of cardiac pathologies
Braga Identification and Characterization of MicroRNAs Modulating Cardiac Hypertrophy
유호진 miR-145 regulates non homologus end joning by targeting DNA-PKC's
Engelhardt et al. Mir-378 controls cardiac hypertophy by combined repression of map kinase pathway factors
Farina Regulation of cadherin-11 by GSK3 inhibition and TGFβ1 treatment in cancer cells
Sundaravinayagam P65/RelA is involved in translational repression of Fanconi Anemia protein FANCM via up-regulation of MiR-146a
EP2364324A1 (en) Use of inhibitors of plac8 activity for the modulation of adipogenesis
Ganesan The role of microRNA-378 in cardiac hypertrophy
Cheever MicroRNA-mediated regulation and the fragile X family of proteins